1. Home
  2. NIE vs ERAS Comparison

NIE vs ERAS Comparison

Compare NIE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$26.61

Market Cap

655.6M

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$10.37

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIE
ERAS
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
655.6M
5.5B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NIE
ERAS
Price
$26.61
$10.37
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$14.25
AVG Volume (30 Days)
52.2K
9.6M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
9.04%
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.74
$1.06
52 Week High
$26.73
$24.28

Technical Indicators

Market Signals
Indicator
NIE
ERAS
Relative Strength Index (RSI) 74.23 36.46
Support Level $24.71 $2.07
Resistance Level N/A $16.14
Average True Range (ATR) 0.31 1.41
MACD 0.06 -0.70
Stochastic Oscillator 86.62 10.65

Price Performance

Historical Comparison
NIE
ERAS

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: